These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Determination of serum RP11-731F5.2 as a noninvasive biomarker for gastric cancer diagnosis and prognosis.
    Author: Jing R, Liu S, Jiang Y, Zong W, Ju S, Cui M.
    Journal: Pathol Res Pract; 2020 Dec; 216(12):153261. PubMed ID: 33176259.
    Abstract:
    BACKGROUND: Gastric cancer (GC) is one of malignant tumor with the highest incidence and mortality in the world. The long noncoding RNA (lncRNA) play an important role in GC. We aim to systematically evaluate the clinical values of lncRNA RP11-731F5.2 in GC. METHODS: We evaluated the level of serum RP11-731F5.2 by the reverse transcription and quantitative real-time PCR. The study involved following aspects: (1) confirmation of the higher RP11-731F5.2 level in serum specimens of GC; (2) evaluation of efficacy monitoring value by the serum RP11-731F5.2 assay in GC; (3) evaluation of the prognostic value by the serum RP11-731F5.2 assay in GC. RESULTS: The level of RP11-731F5.2 stably present in the serum of GC patients (median [interquartile range, IQR 25-75]: 1.495 [0.912-2.367]) was significantly higher than that in healthy controls (0.620 [0.400-1.222]) (P < 0.001). Combined with RP11-731F5.2, CEA and CA19-9, the area under the curve was the largest (0.84, 95 % confidence interval, 0.77-0.90), which can significantly improve the diagnostic efficacy of GC. Moreover, the level of serum RP11-731F5.2 in postoperative samples decreased significantly compared with the level of preoperative samples (2.415 [1.558-3.115] versus 2.007 [1.112-2.711], P = 0.029). There was difference in survival time between GC patients containing higher level of RP11-731F5.2 and those with lower level of RP11-731F5.2 (P = 0.048). CONCLUSION: Our study suggested that circulating RP11-731F5.2 may be employed as a novel diagnostic, efficacy monitoring and prognostic biomarker for GC.
    [Abstract] [Full Text] [Related] [New Search]